Evidence map›Paper›PMID 31587095›Full record

ArticleCancer chemotherapy and pharmacology2019

Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.

Fernando Rivera, C Romero, P Jimenez-Fonseca, M Izquierdo-Manuel, A Salud, E Martínez, M Jorge, V Arrazubi, J C Méndez, P García-Alfonso and 5 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Fernando RiveraMedical Oncology Department, Hospital Universitario Marqués de Valdecilla and Instituto de Investigación Marqués de Valdecilla (IDIVAL), Avda Valdecilla SN, 39008, Santander, Spain. Fernando.rivera@scsalud.es.ORCID http://orcid.org/0000-0003-4962-3949
C RomeroMedical Oncology Department, POVISA, Vigo, Spain.
P Jimenez-FonsecaMedical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
M Izquierdo-ManuelMedical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
A SaludMedical Oncology Department, Hospital Arnau de Vilanova, Lleida, Spain.
E MartínezMedical Oncology Department, Hospital Universitario Marqués de Valdecilla and Instituto de Investigación Marqués de Valdecilla (IDIVAL), Avda Valdecilla SN, 39008, Santander, Spain.
M JorgeMedical Oncology Department, Hospital Xeral Cies, Vigo, Spain.
V ArrazubiMedical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
J C MéndezMedical Oncology Department, Centro Oncológico de Galicia, Coruña, Spain.
P García-AlfonsoMedical Oncology Department, Hospital Gregorio Marañón, Madrid, Spain.
M ReboredoMedical Oncology Department, Complejo Hospitalario de A Coruña, Coruña, Spain.
J BarriusoMedical Oncology Department, Hospital La Paz, Madrid, Spain.
N Muñoz-UncetaMedical Oncology Department, Hospital Universitario Marqués de Valdecilla and Instituto de Investigación Marqués de Valdecilla (IDIVAL), Avda Valdecilla SN, 39008, Santander, Spain.
R JimenoMedical Oncology Department, Hospital Universitario Marqués de Valdecilla and Instituto de Investigación Marqués de Valdecilla (IDIVAL), Avda Valdecilla SN, 39008, Santander, Spain.
C LópezMedical Oncology Department, Hospital Universitario Marqués de Valdecilla and Instituto de Investigación Marqués de Valdecilla (IDIVAL), Avda Valdecilla SN, 39008, Santander, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine.

Identifiers

PMID31587095
PMCPMC6820607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.